Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation

Benjamin Duhart, Marsha R. Honaker, M. H. Shokouh-Amiri, C. A. Riely, S. R. Vera, S. L. Taylor, A. H. Al-Jedai, A. O. Gaber

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long-term immunosuppression in hepatitis B core antibody (HBcAb)-positive, hepatitis B surface antigen (HBsAg)-negative transplant recipients has not been clearly described. Herein, we present a long-term follow-up for 49 HBcAb-positive, HBsAg-negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76%) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41%) of the recipients with either tacrolimus (33 [67%])- or cyclosporine (16 [33%])-based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B] immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow-up was 3.1 ± 1.4 years. At the last follow-up, overall patient and graft survival were 98% and 96%, respectively. Patient survival was 96% in liver, 100% in kidney, and 100% in pancreas transplant recipients. The graft survival for each organ type was 93% in liver, 100% in kidney, and 75% in pancreas transplant recipients at the end of follow-up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb-positive, HBsAg-negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates.

Original languageEnglish (US)
Pages (from-to)126-131
Number of pages6
JournalTransplant Infectious Disease
Volume5
Issue number3
DOIs
StatePublished - Sep 1 2003

Fingerprint

Hepatitis B virus
Transplantation
Hepatitis B Surface Antigens
Hepatitis B Antibodies
Immunosuppression
Graft Survival
Pancreas
Lamivudine
Kidney
Liver
Active Immunity
Incidence
Tacrolimus
Virus Diseases
Immunosuppressive Agents
Hepatitis B
Cyclosporine
Immunoglobulins
Survival Rate
Maintenance

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Transplantation

Cite this

Duhart, B., Honaker, M. R., Shokouh-Amiri, M. H., Riely, C. A., Vera, S. R., Taylor, S. L., ... Gaber, A. O. (2003). Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transplant Infectious Disease, 5(3), 126-131. https://doi.org/10.1034/j.1399-3062.2003.00021.x

Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. / Duhart, Benjamin; Honaker, Marsha R.; Shokouh-Amiri, M. H.; Riely, C. A.; Vera, S. R.; Taylor, S. L.; Al-Jedai, A. H.; Gaber, A. O.

In: Transplant Infectious Disease, Vol. 5, No. 3, 01.09.2003, p. 126-131.

Research output: Contribution to journalReview article

Duhart, B, Honaker, MR, Shokouh-Amiri, MH, Riely, CA, Vera, SR, Taylor, SL, Al-Jedai, AH & Gaber, AO 2003, 'Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation', Transplant Infectious Disease, vol. 5, no. 3, pp. 126-131. https://doi.org/10.1034/j.1399-3062.2003.00021.x
Duhart, Benjamin ; Honaker, Marsha R. ; Shokouh-Amiri, M. H. ; Riely, C. A. ; Vera, S. R. ; Taylor, S. L. ; Al-Jedai, A. H. ; Gaber, A. O. / Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. In: Transplant Infectious Disease. 2003 ; Vol. 5, No. 3. pp. 126-131.
@article{edc4cc9804294c14917f25c381f05cba,
title = "Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation",
abstract = "Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long-term immunosuppression in hepatitis B core antibody (HBcAb)-positive, hepatitis B surface antigen (HBsAg)-negative transplant recipients has not been clearly described. Herein, we present a long-term follow-up for 49 HBcAb-positive, HBsAg-negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76{\%}) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41{\%}) of the recipients with either tacrolimus (33 [67{\%}])- or cyclosporine (16 [33{\%}])-based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B] immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow-up was 3.1 ± 1.4 years. At the last follow-up, overall patient and graft survival were 98{\%} and 96{\%}, respectively. Patient survival was 96{\%} in liver, 100{\%} in kidney, and 100{\%} in pancreas transplant recipients. The graft survival for each organ type was 93{\%} in liver, 100{\%} in kidney, and 75{\%} in pancreas transplant recipients at the end of follow-up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb-positive, HBsAg-negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates.",
author = "Benjamin Duhart and Honaker, {Marsha R.} and Shokouh-Amiri, {M. H.} and Riely, {C. A.} and Vera, {S. R.} and Taylor, {S. L.} and Al-Jedai, {A. H.} and Gaber, {A. O.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1034/j.1399-3062.2003.00021.x",
language = "English (US)",
volume = "5",
pages = "126--131",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation

AU - Duhart, Benjamin

AU - Honaker, Marsha R.

AU - Shokouh-Amiri, M. H.

AU - Riely, C. A.

AU - Vera, S. R.

AU - Taylor, S. L.

AU - Al-Jedai, A. H.

AU - Gaber, A. O.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long-term immunosuppression in hepatitis B core antibody (HBcAb)-positive, hepatitis B surface antigen (HBsAg)-negative transplant recipients has not been clearly described. Herein, we present a long-term follow-up for 49 HBcAb-positive, HBsAg-negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76%) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41%) of the recipients with either tacrolimus (33 [67%])- or cyclosporine (16 [33%])-based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B] immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow-up was 3.1 ± 1.4 years. At the last follow-up, overall patient and graft survival were 98% and 96%, respectively. Patient survival was 96% in liver, 100% in kidney, and 100% in pancreas transplant recipients. The graft survival for each organ type was 93% in liver, 100% in kidney, and 75% in pancreas transplant recipients at the end of follow-up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb-positive, HBsAg-negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates.

AB - Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long-term immunosuppression in hepatitis B core antibody (HBcAb)-positive, hepatitis B surface antigen (HBsAg)-negative transplant recipients has not been clearly described. Herein, we present a long-term follow-up for 49 HBcAb-positive, HBsAg-negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76%) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41%) of the recipients with either tacrolimus (33 [67%])- or cyclosporine (16 [33%])-based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B] immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow-up was 3.1 ± 1.4 years. At the last follow-up, overall patient and graft survival were 98% and 96%, respectively. Patient survival was 96% in liver, 100% in kidney, and 100% in pancreas transplant recipients. The graft survival for each organ type was 93% in liver, 100% in kidney, and 75% in pancreas transplant recipients at the end of follow-up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb-positive, HBsAg-negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates.

UR - http://www.scopus.com/inward/record.url?scp=0242354871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242354871&partnerID=8YFLogxK

U2 - 10.1034/j.1399-3062.2003.00021.x

DO - 10.1034/j.1399-3062.2003.00021.x

M3 - Review article

C2 - 14617300

AN - SCOPUS:0242354871

VL - 5

SP - 126

EP - 131

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 3

ER -